Proton pump inhibitors - possible side effects of long-term therapy: a review
DOI:
https://doi.org/10.12775/QS.2024.36.56387Keywords
Proton Pump Inhibitors, Vitamin Deficiency, Omprezaole, Gastric cancerAbstract
Introduction and purpose: Proton pump inhibitors (PPIs), which have been on the market for more than 30 years, are widely regarded as safe and effective medications. For this reason, they are very popular with both doctors and patients. PPIs find their use in the treatment of such ailments as gastroesophageal reflux, gastric ulcer disease or as a shielding therapy when taking non-steroidal anti-inflammatory drugs. Nevertheless, their long-term use may be associated with many side effects. The purpose of our review is to summarize the knowledge in the current medical literature on the possible complications of chronic use of PPIs.
The review is based on 30 articles from the most recent publications on chronic PPI treatment. Publications were searched for the words PPI chronic therapy, gastric cancer, omeprazole in PubMed databases. Articles from 2018-2024 represent 70% of all publications from the references.
A brief description of the state of knowledge: Although the use of PPIs in the short term is relatively safe, the number of people taking these drugs has increased significantly in recent years. They are prescribed not always as indicated, patients often take them for too long - this in turn leads to an increasing incidence of side effects. Some of them can permanently affect health and significantly reduce the comfort of life - such as kidney diseases, cardiovascular disorders or gastric cancer.
Summary: Considering the widespread availability and popularity of PPIs, it is important to adequately educate both patients and healthcare professionals of the possible side effects. It is crucial to use medications as prescribed, with an appropriate assessment of the risk-benefit ratio. It might result in reducing health care expenditures to deal with the consequences of IPP therapy.
References
Yibirin M, De Oliveira D, Valera R, et al. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021;13(1):e12759. Published 2021 Jan 18. doi:10.7759/cureus.12759
Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-715. doi:10.1053/j.gastro.2017.01.031
Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016;176(2):238-246. doi:10.1001/jamainternmed.2015.7193
Xie Y, Bowe B, Li T, et al. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153-3163. doi:10.1681/ASN.2015121377
Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115-127. doi:10.4068/cmj.2023.59.2.115
Kazberuk M, Brzósko S, Hryszko T, et al. Overuse of proton pump inhibitors and its consequences. Adv Clin Exp Med. (2016);70(null):1112-1116. https://doi.org/10.5604/17322693.1222106.
Niklasson A, Lindström L, Simrén M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105(7):1531-1537. doi:10.1038/ajg.2010.81
Waldum H, Mjønes P. The central role of gastrin in gastric cancer. Front Oncol. 2023;13:1176673. Published 2023 Oct 24. doi:10.3389/fonc.2023.1176673
Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13-21. doi:10.1016/j.therap.2020.06.019
Gumprecht J, Długaszek M, Niemczyk A et al. Is it necessary to be afraid of vitamin B12 deficiency during metformin treatment? Clin Diabetol 2016; 5, 6: 195–198. DOI: 10.5603/DK.2016.0033.
Mumtaz H, Ghafoor B, Saghir H, et al. Association of Vitamin B12 deficiency with long-term PPIs use: A cohort study. Ann Med Surg (Lond). 2022;82:104762. Published 2022 Sep 26. doi:10.1016/j.amsu.2022.104762
Choudhury A, Jena A, Jearth V, et al. Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2023;17(5):479-487. doi:10.1080/17474124.2023.2204229
Henry EB, Carswell A, Wirz A, et al. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther. 2005;22(6):539-545. doi:10.1111/j.1365-2036.2005.02568.x
Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125-133. doi:10.1177/2042098613482484
Benmassaoud A, McDonald EG, Lee TC. Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. CMAJ. 2016;188(9):657-662. doi:10.1503/cmaj.150570
Targownik LE, Goertzen AL, Luo Y, et al. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. Am J Gastroenterol. 2017;112(1):95-101. doi:10.1038/ajg.2016.481
Song HJ, Jiang X, Henry L, et al. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(6):851-866. doi:10.1007/s00228-020-02854-8
Bhatnagar MS, Choudhari S, Pawar D, et al. Long-Term Use of Proton-Pump Inhibitors: Unravelling the Safety Puzzle. Cureus. 2024;16(1):e52773. Published 2024 Jan 23. doi:10.7759/cureus.52773
Pourhadi N, Janbek J, Jensen-Dahm C, et al. Proton pump inhibitors and dementia: A nationwide population-based study. Alzheimers Dement. 2024;20(2):837-845. doi:10.1002/alz.13477
Cooksey R, Kennedy J, Dennis MS, et al. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One. 2020;15(9):e0237676. Published 2020 Sep 18. doi:10.1371/journal.pone.0237676
Shih CJ, Chen YT, Ou SM, et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292-297. doi:10.1016/j.ijcard.2014.09.036
Ariel H, Cooke JP. Cardiovascular Risk of Proton Pump Inhibitors. Methodist Debakey Cardiovasc J. 2019;15(3):214-219. doi:10.14797/mdcj-15-3-214
Maret-Ouda J, Panula J, Santoni G, et al. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study. J Gastroenterol. 2023;58(8):734-740. doi:10.1007/s00535-023-02007-5
Revaiah PC, Kochhar R, Rana SV, et al. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. JGH Open. 2018;2(2):47-53. Published 2018 Apr 2. doi:10.1002/jgh3.12045
Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-490. doi:10.1016/j.cgh.2012.12.011
Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500-6515. doi:10.3748/wjg.v23.i35.6500
Abrahami D, McDonald EG, Schnitzer ME, et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71(1):16-24. doi:10.1136/gutjnl-2021-325097
Kim JW, Jung HK, Lee B, et al. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study. Eur J Clin Pharmacol. 2023;79(12):1699-1708. doi:10.1007/s00228-023-03580-7
Aydın Yoldemir Ş, Zeren Ozturk G, Akarsu M, et al. Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?. Wien Klin Wochenschr. 2022;134(3-4):104-109. doi:10.1007/s00508-021-01834-x
Srinutta T, Chewcharat A, Takkavatakarn K, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore). 2019;98(44):e17788. doi:10.1097/MD.0000000000017788
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jan Kowalewski, Damian Bęben, Grzegorz Pyc, Łukasz Kowalewski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 120
Number of citations: 0